Meeting Banner
Abstract #0859

Deuterium Metabolic Imaging (DMI) of glucose metabolism in patients with brain tumors.

Henk M. De Feyter1, Zachary A. Corbin2, Isabel P. Prado3, Robert K. Fulbright1, Douglas L. Rothman1, and Robin A. de Graaf1

1Radiology and Biomedical Imaging, Yale University, New Haven, CT, United States, 2Neurology, Yale University, New Haven, CT, United States, 3Yale University, New Haven, CT, United States

Deuterium Metabolic Imaging (DMI) is a novel approach providing high 3D spatial resolution metabolic data from both animal models and human subjects. DMI relies on 2H MRSI in combination with administration of 2H-labeled substrates. Here we describe the first experiences with using DMI to map steady state metabolism of orally administered [6,6’-2H2]-glucose in patients diagnosed with a brain tumor. DMI revealed striking image contrast based on regional differences of glucose metabolism, with high-grade tumor lesions depicting metabolite labeling with consistently high lactate production and low glucose oxidation, a metabolic phenotype known as the Warburg effect.

This abstract and the presentation materials are available to members only; a login is required.

Join Here